Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Biogen
Biogen
Sage’s recent trial failure adds pressure to its two-drug Biogen collab
Pharma Voice
Mon, 07/29/24 - 10:29 am
SAGE Therapeutics
Biogen
clinical trials
SAGE-324
essential tremor
Zurzuvae
postpartum depression
Eisai and Biogen's Alzheimer's med Leqembi turned down in Europe
Fierce Pharma
Fri, 07/26/24 - 11:15 am
Eisai
Biogen
Leqembi
Europe
Biogen, Sage Scrap Essential Tremor Study After Phase II Failure
BioSpace
Wed, 07/24/24 - 11:55 am
Biogen
SAGE Therapeutics
clinical trials
essential tremors
BIIB124
SAGE-324
Ionis plots next steps for Angelman drug Biogen passed on
BioPharma Dive
Tue, 07/23/24 - 11:15 am
Ionis Pharmaceuticals
Biogen
Angelman Syndrome
ION582
Leqembi sales inch higher; Spark’s pivot leads to layoffs
BioPharma Dive
Fri, 07/12/24 - 11:29 am
Eisai
Biogen
Leqembi
Alzheimer's disease
Roche
Spark Therapeutics
gene therapy
layoffs
Eisai and Biogen launch Alzheimer's drug Leqembi in China
Reuters
Fri, 06/28/24 - 11:18 am
Eisai
Biogen
Alzheimer's disease
Leqembi
China
Don’t call it a comeback: Biotech’s CNS resurgence forges Big Pharma connections
Pharma Voice
Fri, 06/28/24 - 11:17 am
Big Pharma
Neuroscience
Prothena Biosciences
Biogen
Eisai
Pfizer
AbbVie
Eli Lilly
Bristol Myers Squibb
What Would a Donanemab Approval Mean for Leqembi?
BioSpace
Mon, 06/24/24 - 10:47 am
Eli Lilly
donanemab
Biogen
Eisai
Leqembi
FDA
Alzheimer's disease
Biogen’s HI-Bio Buy Is Latest Biopharma Spending Spree in Projected $257B Immunology Market
BioSpace
Wed, 06/12/24 - 11:09 am
Biogen
Hi-Bio
M&A
FDA accepts Eisai's subcutaneous Leqembi filing, sets January 25 decision date
Fierce Pharma
Mon, 06/10/24 - 11:19 am
Eisai
Biogen
Leqembi
FDA
Alzheimer's disease
Biogen, Delta soar together to improve air travel accessibility
Medical Marketing and Media
Thu, 06/6/24 - 09:09 pm
Biogen
philanthropy
SMA
mobility
Novartis, Roche unit and others face Italy antitrust probe over eye drug
Reuters
Thu, 06/6/24 - 11:34 am
Novartis
Roche
Genentech
Italy
antitrust
Biogen
Samsung Bioepis
Byooviz
Companies to watch for potential M&As in 2024
BioSpace
Wed, 06/5/24 - 11:31 am
M&A
Vertex Pharmaceuticals
Regeneron
Biogen
Moderna Therapeutics
European Commission grants marketing approval to Biogen's ALS drug
Reuters
Thu, 05/30/24 - 11:05 pm
Biogen
Europe
Ionis Pharmaceuticals
ALS
Qalsody
Biogen to buy Human Immunology Biosciences in deal worth up to $1.8B
Medical Marketing and Media
Wed, 05/22/24 - 11:38 am
Biogen
Human Immunology Biosciences
M&A
FDA approves two biosimilars to blockbuster eye drug Eylea
Reuters
Mon, 05/20/24 - 11:23 am
Regeneron
Eylea
FDA
biosimilars
Biocon Biologics
Yesafli
Opuviz
Samsung BioLogics
Biogen
Biogen walks away from Ionis-partnered ALS, Angelman prospects after peek at clinical data
Fierce Biotech
Thu, 05/16/24 - 11:38 am
Biogen
Ionis Pharmaceuticals
ALS
Angelman Syndrome
Winners and Losers in Biopharma’s Q1 2024 Earnings Season
BioSpace
Wed, 05/15/24 - 11:30 am
earnings
Amgen
AstraZeneca
Novo Nordisk
Biogen
Bristol Myers Squibb
JNJ
Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA
Reuters
Tue, 05/14/24 - 11:03 pm
Eisai
Biogen
Leqembi
FDA
Alzheimer's disease
Biogen: Don’t expect any big acquisitions this year
BioPharma Dive
Wed, 04/24/24 - 09:31 pm
Biogen
Pharma CEOs
Chris Viehbacher
M&A
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »